Nanomedicine-induced programmed cell death enhances tumor immunotherapy

Jiaye Lu; Zongguang Tai; Junchao Wu; Lisha Li; Tingrui Zhang; Jun Liu; Quangang Zhu; Zhongjian Chen

doi:10.1016/j.jare.2023.09.018

Nanomedicine-induced programmed cell death enhances tumor immunotherapy

J Adv Res. 2023 Sep 22:S2090-1232(23)00267-9. doi: 10.1016/j.jare.2023.09.018. Online ahead of print.

Authors

Jiaye Lu¹, Zongguang Tai², Junchao Wu¹, Lisha Li¹, Tingrui Zhang¹, Jun Liu², Quangang Zhu³, Zhongjian Chen⁴

Affiliations

¹ School of Medicine, Shanghai University, 99 Shangda Road, Shanghai 200444, China; Shanghai Skin Disease Hospital, School of Medicine, Tongji University, 1278 Baode Road, Shanghai 200443, China.
² Shanghai Skin Disease Hospital, School of Medicine, Tongji University, 1278 Baode Road, Shanghai 200443, China.
³ Shanghai Skin Disease Hospital, School of Medicine, Tongji University, 1278 Baode Road, Shanghai 200443, China. Electronic address: qgzhu@126.com.
⁴ School of Medicine, Shanghai University, 99 Shangda Road, Shanghai 200444, China; Shanghai Skin Disease Hospital, School of Medicine, Tongji University, 1278 Baode Road, Shanghai 200443, China. Electronic address: aajian818@163.com.

PMID: 37743016
DOI: 10.1016/j.jare.2023.09.018

Abstract

Background: There has been widespread concern about the high cancer mortality rate and the shortcomings of conventional cancer treatments. Immunotherapy is a novel oncology therapy with high efficiency and low side effects, which is a revolutionary direction for clinical oncology treatment. However, its clinical effectiveness is uneven. Based on the redefinition and reclassification of programmed cell death (PCD) (divided into necroptosis, ferroptosis, pyroptosis, and autophagy), the role of nanomedicine-induced PCD in cancer therapy has also received significant attention. Clinical and preclinical studies have begun to combine PCD with immunotherapy.

Aim of review: In this article, we present recent research in tumor immunotherapy, provide an overview of how nanomedicine-induced PCD is involved in tumor therapy, and review how nanomedicine-induced PCD can improve the limitations of immunotherapy to enhance tumor immunotherapy. The future development of nanomedicine-mediated PCD tumor therapy and tumor immunotherapy is also proposed Key scientific concepts of overview Nanomedicine-induced PCD is a prospective method of tumor immunotherapy. Nanomedicines increase tumor site penetration and targeting ability, and nanomedicine-mediated PCD activation can stimulate powerful anti-tumor immune effects, which has a good contribution to immunotherapy of tumors.

Keywords: Immunotherapy; Nanomedicine; Programmed cell death; Tumor.

Publication types

Review